Review anchor
Prostaglandin E2 receptor EP2 subtype
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
Evidence Snapshot
Prostaglandin E2 receptor EP2 subtype
CHEMBL4909
SINGLE PROTEIN
Rattus norvegicus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Prostaglandin E2 receptor EP2 subtype as ChEMBL target CHEMBL4909, mapped to UniProt Q62928. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4909
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q62928
Prostaglandin E2 receptor EP2 subtype
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Prostaglandin E2 receptor EP2 subtype matters
Prostaglandin E2 receptor EP2 subtype is reviewed as Prostaglandin E2 receptor EP2 subtype (UniProt Q62928); the current evidence base includes 2 approved drugs, 80 compounds, and 11 assays, with lead potency reaching pChEMBL 9.7.
Protein context
Prostaglandin E2 receptor EP2 subtype
Prostaglandin E2 receptor EP2 subtype Sequence length is 357 aa.
Review this target as Prostaglandin E2 receptor EP2 subtype, mapped to UniProt Q62928. Sequence length is 357 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q62928
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 2 approved drugs, 80 compounds, and 11 assays for this target. The dominant activity type is IC50. CHEMBL548 is the current potency anchor at pChEMBL 9.7.
Use CHEMBL548 as the tractability anchor when discussing potency (pChEMBL 9.7).
Activity source · ChEMBL 36 via Core Engine
2 approved
pChEMBL 9.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Prostaglandin E2 receptor EP2 subtype matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q62928, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
80
Total Compounds
11
Total Assays
2
Approved Drugs
IC50: 61.0, KI: 1.0, EC50: 50.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL548
|
9.7 | EC50 | Approved |
|
|
No preferred name
CHEMBL559065
|
9.7 | EC50 | — |
|
|
No preferred name
CHEMBL563646
|
9.5 | EC50 | Clinical |
|
|
No preferred name
CHEMBL541517
|
9.0 | EC50 | — |
|
|
No preferred name
CHEMBL541516
|
8.6 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
DINOPROSTONE
CHEMBL548
|
1977 |
Source Header